Companies › Canwell Biotech
3 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CAN016 | – | Phase 1 | Patients With Advanced Solid Tumors | Dec 2028 |
| CAN1012 selective TLR7 agonist | – | Phase 1 | Solid Tumor; Ductal Carcinoma in Situ | – |
| CAN2109 | – | Phase 1 | Solid Tumor | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06332430 | CAN2109 | Phase 1 | Solid Tumor | Oncology | May 2025 |
| NCT05580991 | CAN1012 | Phase 1 | Solid Tumor | Oncology | Jun 2025 |
| NCT07664150 | CAN016 | Phase 1 | Patients With Advanced Solid Tumors | Oncology | Dec 2028 |
| NCT07408856 | CAN1012 | Phase 1 | Ductal Carcinoma in Situ | Oncology | May 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.